No Emergent Resistance in HIV-1 Infected Virologically-Suppressed Subjects Who Switched to R/F/TAF

BACKGROUND: GS-US-366-1216 and GS-US-366-1160 are randomized, double-blind, phase 3b studies evaluating the safety and efficacy of switching to rilpivirine/emtricitabine/tenofovir alafenamide (R/F/TAF) from R/F/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/F/TDF, respectively, in HIV-1-infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Porter, Danielle, Kulkarni, Rima, Cao, Huyen, Sengupta, Devi, White, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630830/
http://dx.doi.org/10.1093/ofid/ofx163.1077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630830/
http://dx.doi.org/10.1093/ofid/ofx163.1077

Ejemplares similares